薄芝糖肽对肝癌大鼠的T淋巴细胞亚群和DC细胞的影响研究  

Effects Bozhi glycopeptide on T lymphocyte subsets and DC cells in hepatocarcinoma rats

作　　者：何敏[1] 侯延丽[1] 牛育鸿[1] 白宝平[1] 岳鹏莹[1] HE Min;HOU Yanli;NIU Yuhong;BAI Baoping;YUE Pengying(Xi＇an Institute of Innovation,Yan＇an University,Xi＇an 710010,China)

机构地区：[1]延安大学西安创新学院,西安710010

出　　处：《免疫学杂志》2018年第10期836-842,共7页Immunological Journal

基　　金：陕西省教育厅科学研究项目(17JK1173)

摘　　要：目的探讨薄芝糖肽对肝癌大鼠的T淋巴细胞亚群和DC细胞的影响。方法取43只大鼠,其中3只用于制备癌性腹水,另32只注射癌性腹水建立肝癌模型后随机分为模型组及低、中、高剂量组,其余8只为健康组。3剂量组每天腹腔注射50、100、200 mg/L的薄芝糖肽溶液,健康组及模型组注射等量无菌生理盐水。15 d后检测并对比各组T淋巴细胞亚群CD3^+、CD4^+、CD8^+、CD4^+/CD8^+水平及DC细胞表面协同刺激分子CD80^+、CD86^+、MHC-Ⅱ阳性表达率、IL-2、IL-10水平,对比各剂量组抑瘤率。结果 CD3^+、CD4^+、CD4^+/CD8^+水平及CD80^+、CD86^+、MHC-Ⅱ阳性表达率及血清IL-2含量组间比较,健康组最高、中剂量组其次、低、高剂量组稍低、模型组最低,除低、高剂量组相比差异不显著(P>0.05),其他每2组间比较差异均显著(P<0.05);CD8^+及血清IL-10含量组间比较,健康组最低、中剂量组其次、低、高剂量组稍高、模型组最高,除低、高剂量组相比差异不显著(P>0.05),其他每2组间比较差异均显著(P<0.05);抑瘤率组间比较,中剂量组显著高于低、高剂量组(P<0.05),低、高剂量组抑瘤率相比差异不显著(P>0.05)。结论薄芝糖肽通过调节T淋巴细胞亚群及DC细胞表面标志物表达,增强机体T细胞免疫功能,促进DC细胞成熟,从而增强机体免疫力,达到良好的辅助抗肿瘤效果,其中100 mg/L薄芝糖肽增强机体免疫力、辅助抗肿瘤效果最佳。To investigate the effect of Bozhi glycopeptide on T lymphocyte subgroups and dendritic （DC） cells in liver cancer rats, total of 43 rats were recruited, among which 3 SD rats were used to prepare ancerous aseites, another 32 rats injected with the aneerous ascites were randomly divided into model group and low, medium and high dose groups after liver cancer model were established with 8 rats in each group, and the other 8 rats were set as healthy control group. The 3 doses groups of rats were injected intraperitoneally with 50, 100, 200 mg/L Bozhi glycopeptide, while the healthy group and the model group were injected with aseptic saline. Fifteen days later, the levels of T lymphocyte subgroups CD3^＋, CD4^＋, CD8^＋, CD4^＋/CD8^＋ and the positive rates of CD80^＋, CD86^＋, MHC- 11 of DC cells surface molecules were compared. Furthermore, the contents of serum interleukin-2 （[L-2）, interleukin （IL-IO） and the rates of tumor inhibition were compared. Data showed that the levels of CD3^＋, CD4^＋, CD4^＋/CD8^＋, the positive rates of CD80^＋, CD86^＋, MHC-Ⅱ and the content of serum IL-2 in the health group were the highest, in medium dose group were the second, in the low and high dose groups were slightly lower, in the model group were the lowest, and these indexes were significant differences between each two groups, except between the low and high dose groups. The levels of CD8^＋ and the content of serum IL-10 in the health group were the lowest, in medium dose group were the second, i high dose groups were slightly higher, group were the highest, and these n the low and in the model indexes were significant differences between each two groups, except between the low and high dose groups. Tumor inhibition rate of the medium dose group was significantly higher than those the low and high dose groups, while there was no statistically significant difference between the low and medium dose group. In conclusion, the Bozhi glycopeptide can regulate the surface markers expression of DC c

关 键 词：薄芝糖肽 肝癌 T淋巴细胞亚群 DC细胞 

分 类 号：R735.7[医药卫生—肿瘤]